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Abstract 
Increased proinsulin secretion, which characterizes type 2 diabetes and insulin resistance, may be 
due to an intrinsic, primitive defect in proinsulin processing, or be secondary to increased demand 
on β-cells (hyperinsulinemia secondary to insulin resistance). An alternative way to investigate the 
relation between relative hyperproinsulinemia and increased secretory demand is to study the 
dynamic changes in proinsulin to insulin ratio after partial pancreatectomy, a model of acute 
increased beta cell workload on the remaining pancreas. To pursue this aim, non-diabetic patients, 
scheduled for partial pancreatectomy, underwent 4-hour mixed meal tests and hyperinsulinemic 
euglycemic clamps before and after surgery. Following acute beta cell mass reduction, no changes 
were observed in fasting proinsulin to insulin ratio, while fold change in proinsulin to insulin ratio 
significantly increased over time after the meal. Further, our data demonstrate that whole-body 
insulin resistance is associated with underlying defects in proinsulin secretion, which become 
detectable only in the presence of increased insulin secretion demand. 
 
INTRODUCTION 
Increased circulating levels of proinsulin, and a consequently elevated proinsulin-to-insulin ratio, is 
a well-known abnormality in type 2 diabetes (1-4). Disproportionate proinsulin secretion has been 
reported as marker for beta cell dysfunction in both diabetic patients and individuals at risk of 
diabetes (5,6).  The exact mechanism behind this increase is unknown, although it has been 
hypothesized that an elevated proinsulin-to-insulin ratio is caused by increased secretory demand on 
beta cells due to insulin resistance and continuous hyperglycemia, which promotes the release of 
immature granules with a higher relative content of proinsulin and its conversion intermediates. 
Experimental studies in nicotinic-acid-induced insulin resistance in baboons (7) and humans (8), 
and observations in non-diabetic obese subjects (9), which show unchanged proinsulin-to-insulin 
ratios, however, do not support the above hypothesis. Further, it has also been shown that an 
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elevated proinsulin-to-insulin ratio in type 2 diabetes is highly correlated with the degree of 
decreased secretory capacity (10). However, it is still unclear how beta cell dysfunction per se or 
increased beta cell demand relates to conversion of intact proinsulin to insulin, or whether a 
combination of insulin resistance, beta cell dysfunction and increased beta cell demand has a 
differential effect on this conversion process. 
To investigate the relation between relative hyperproinsulinemia and increased secretory demand, 
we examined the effects of acute ~50 % reduction of islet mass, and concomitant increased beta cell 
workload on the remaining ~50% islet mass, using partial pancreatectomy as a human model. 
Several previous studies have examined the metabolic changes occurring following partial 
pancreatectomy in humans (11,12). Due to anatomical reasons (the head/right part of the pancreas 
is vascularized by branches of the gastroduodenal artery, while the tail is vascularized by 
branches of the splenic artery) all  patients undergoing pancreaticoduodenectomy receive virtually 
the same partial (50%) resection, maintaining almost the same remaining portion of the endocrine 
pancreas.  This surgery is therefore a unique way to examine the effects of a sudden increase in 
the workload of the remaining pancreas. 
Furthermore, it is unclear which pre-surgery metabolic defects have a greater impact on post-
challenge glucose tolerance and islet function. This issue is particularly relevant because 
metabolic response differs among subjects who undergo a 50% partial pancreatectomy, 
suggesting that underlying insulin resistance could play a major role. 
Therefore, in the present study we aim: (1) to examine changes in proinsulin secretion and beta cell 
secretory capacity, modeled from a 4h mixed meal test, in non-diabetic individuals before and after 
acute beta cell reduction and (2) to assess whether preexisting insulin resistance can modify 
proinsulin processing subsequent to increased beta cell workload. 
RESEARCH DESIGN AND METHODS 
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Subject selection and protocols 
Nine patients (7 female; 2 male; mean age 55±7 yrs ±SE) undergoing pylorus-preserving 
pancreatoduodenectomy were recruited from the Digestive Surgery Unit and studied in the Center 
for Endocrine and Metabolic Diseases unit (both at the Agostino Gemelli University Hospital, 
Rome, Italy). The study protocol (ClinicalTrials.gov Identifier: NCT02175459) was approved by 
the local ethics committee (P/656/CE2010 and 22573/14) and all participants provided written 
informed consent, which was followed by a comprehensive medical evaluation. Indication for 
surgery was tumor of the ampulla of Vater. None of the patients enrolled had a known history of 
diabetes. Patients underwent both fasting glucose and HbA1c testing to exclude diabetes, according 
to the American Diabetes Association criteria (13). Only patients with normal cardiopulmonary and 
kidney function, as determined by medical history, physical examination, electrocardiography, 
estimated glomerular filtration rate and urinalysis were included. Altered serum lipase and amylase 
levels prior to surgery, as well as morphologic criteria for pancreatitis, were considered exclusion 
criteria. Patients with severe obesity (BMI> 40), uncontrolled hypertension and/or 
hypercholesterolemia were also excluded. Clinical and metabolic characteristics of patients are 
shown in Table 1. 
All subjects underwent a 2-hour euglycemic clamp (insulin infusion rate: 40 mIU·min
-1
·m
-2
), 
Hyperglycemic clamp with arginine stimulation and a 4-hour mixed meal test to evaluate insulin 
secretion (from C-peptide deconvolution) and proinsulin/insulin ratio, as described below, before 
and ~40 days after surgery. The adequacy of the recovery period was determined on the basis of the 
normalization of inflammatory parameters such as C-reactive protein, erythrocyte sedimentation 
rate, stability of weight, absence of symptoms of abnormal intestinal motility or exocrine pancreatic 
deficiency. 
Hyperinsulinemic euglycemic clamp procedure 
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The hyperinsulinemic euglycemic clamp test was performed after a 12h overnight fast using insulin 
40 mIU·min
-1
·m
-2 
of body surface according to DeFronzo and colleagues (14). A primed-constant 
infusion of insulin was administered (Actrapid HM, Novo Nordisk, Copenhagen, Denmark). The 
constant rate for the insulin infusion was reached within 10 min to achieve steady-state insulin 
levels; in the meantime, a variable infusion of 20% glucose was started via a separate infusion 
pump and the rate was adjusted, on the basis of plasma glucose samples drawn every 5 min, to 
maintain plasma glucose concentration at each participant’s fasting plasma glucose level. During 
the last 20 min of the clamp procedure, plasma samples from blood drawn at 5–10 min intervals 
were used to determine glucose and insulin concentrations. Whole-body peripheral glucose 
utilization was calculated during the last 30-min period of the steady-state insulin infusion and was 
measured as the mean glucose infusion rate (as mg·Kg
-1
·min
-1
). 
Hyperglycemic clamp procedure 
Plasma glucose was clamped at a stable level of 125 mg/dl above fasting blood glucose 
concentration. The hyperglycemic clamp was started with a bolus dose of dextrose 200 mg/mL (150 
mg/kg) administered into the antecubital vein. Blood was drawn from a cannulated dorsal hand vein 
on the opposite arm. Every 5 min, venous plasma glucose was analyzed with a glucose analyzer and 
the infusion of 20% glucose was adjusted to achieve a stable glucose level of 125 mg/dl above the 
fasting value. Serum samples for insulin, and C-peptide were drawn at 0, 2.5, 5, 7.5, 10, 15, 30, 60, 
90, 120, 130, 140, and 150 min. At 120 min, a 5g arginine bolus was administered to measure 
maximum C-peptide secretory capacity at a steady-state blood glucose concentration of 250 mg/dl. 
Arginine-stimulated β cell secretory capacity was calculated as delta of 130 min C-peptide and 120 
min C-peptide levels 
Mixed meal test 
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A mixed meal test (MMT) was performed, as previously described (15). Patients were instructed to 
consume a meal of 830 kcal (107 kcal from protein, 353 kcal from fat, and 360 kcal from 
carbohydrates) within 15 min. Blood samples were drawn twice in the fasting state and at 30 min 
intervals over the following 240 min (sample time 0’, 30’, 60’, 90’, 120’, 150’, 180’, 210’ and 240’) 
for the measurement of plasma glucose, insulin, C-peptide, proinsulin. Blood samples for proinsulin 
were sampled in tubes containing EDTA; after centrifugation (1000 rpm for 10 min at 4°C), they 
were stored at -80°C until analysis. Insulin levels were determined using a commercial RIA kit 
(Medical System, Immulite DPC, Los Angeles, CA). Plasma glucose concentrations were 
determined by the glucose oxidase technique, using a glucose analyzer (Beckman Instruments, Palo 
Alto, CA, USA). Plasma C-peptide was measured by autoDELPHIA automatic fluoroimmunoassay 
(Wallac, Turku, Finland), with a detection limit of 17 pmol/L. Proinsulin was measured by ELISA 
kit no. 10-1118-01 (Mercodia), which reacts specifically with total proinsulin. 
Surgical procedures 
Pancreatoduodenectomy was performed according to the pylorus preserving technique (16). Briefly, 
the pancreatic head, the entire duodenum, common bile duct, and gallbladder were removed en 
bloc, leaving a functioning pylorus intact at the gastric outlet. All adjacent lymph nodes were 
carefully removed. The continuity of the gastrointestinal tract was restored by an end-to-side 
invaginated pancreato-jejunostomy. Further downstream, an end-to-side hepaticojejunostomy and 
an end-to-side pylorojejunostomy were performed. The volume of pancreas removed during the 
surgery is constant (~50%), as previously reported by Schrader et al. (17). 
Calculations 
To further characterize the relation between insulin resistance and changes in proinsulin to insulin 
ratio, we divided subjects according to their insulin sensitivity, as measured by the euglycemic 
hyperinsulinemic clamp procedure before surgery. As previously described (18), the cut-off for 
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insulin sensitivity was the median value of glucose uptake in the overall cohort (4.9 mg·Kg
-1
·min
-1
); 
therefore, subjects whose glucose uptake was above the median value were classified as “more 
insulin-sensitive” than subjects whose glucose uptake was below the median; for ease of 
comprehension, we  defined the subjects as “insulin sensitive” (n.5) or “insulin resistant” (n.4). 
During the mixed meal test, insulin secretion was derived from C-peptide levels by deconvolution 
(19). β-Cell Glucose Sensitivity (βCGS), i.e. the slope of the relationship between insulin secretion 
and glucose concentration, was estimated from the mixed meal by modeling, as previously 
described (20,21). 
Statistics 
All data are expressed as mean ± SEM, unless otherwise indicated. Since samples did not deviate 
significantly from normal, differences in means were tested by two tailed Student’s t test. The 
relationship between variables was derived with linear regression analysis. For measures of insulin, 
C-peptide, proinsulin, proinsulin to insulin ratio, we compared the effects of time and 
pancreatectomy using linear mixed model for repeated measures, with each parameter as the 
dependent variable and time (analyzed as a continuous variable), pancreatectomy and the product 
term of time x pancreatectomy to investigate interaction effects. For proinsulin to insulin ratio, we 
evaluated third level interaction by including a product term of time x pancreatectomy x insulin 
sensitivity in the model. The area under the curve (AUC) of proinsulin to insulin ratio was 
calculated during the 0-240 interval of the mixed meal test using the trapezoidal method. Proinsulin 
to insulin ratio was also calculated as fold change in proinsulin to insulin ratio, dividing each time 
point by the basal level. P-values <0.05 were considered significant. Analysis was performed using 
Stata (StataCorp, TX, USA).  
 
RESULTS 
Clinical and metabolic characteristics of study subjects are provided in Table 1. 
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Hemipancreatectomy induced a marked reduction in basal and total insulin secretion rate, with 
concomitant reduction in glucose sensitivity 
Subjects were evaluated one week before surgery and 40±7 days (range 34-48 days) after surgery, 
as stated in the study design. As expected, both the basal insulin secretion rate (pre-surgery: 
85.3±10.3 vs post-surgery: 57.7±7.59 pmol·min
-1,
m
-2
, P=0.04, Figure 1A) and total insulin secretion 
rate during the meal test (pre-surgery: 69.6±10.9 vs post-surgery: 34.0±4.43 nmol·m
-2
, P=0.01 
Figure 1B) decreased significantly following surgery. Further, partial pancreatectomy also caused a 
significant reduction in βCGS (pre-surgery: 187±46.1 vs post-surgery: 51.7±18.7 pmol·min
-1
m
-
2
·mM
-1
, P<0.01; Figure 1C) and in arginine-stimulated insulin secretion (indirect measure of beta 
cell mass) (pre-surgery: 1691±366,5 vs post-surgery: 632.5±265.8 pmol/L, P=0.02; Figure 1D). To 
provide further proof of increased beta cell workload, we also normalized all insulin secretory 
parameters for  arginine-stimulated insulin secretion. We observed a significant  increase in basal 
ISR (pre-surgery: 0.045±0.005 vs post-surgery: 0.262±0.099, P<0.04; Supplementary figure 1A), 
Total ISR (pre-surgery: 0.040±0.005 vs post-surgery: 0.157±0.050, P<0.03; Supplementary figure 
1B), and also in beta cell glucose sensitivity (pre-surgery: 0.080±0.014 vs post-surgery: 
0.233±0.046, P<0.01; Supplementary figure 1C) perarginine-stimulated insulin secretion following 
acute islet cell mass reduction, which indicates an enhanced beta cell workload in the remaining 
islet cell mass. Conversely, no changes were observed in insulin sensitivity, as assessed by the 
hyperinsulinemic euglycemic clamp (18), after pancreatectomy (pre-surgery: 5.08±0.26 vs post-
surgery: 5.04± 0.17 mg·Kg
-1
·min
-1
, P=0.95). Fasting and plasma glucose concentrations during 
MMT increased significantly after surgery (P<0.01 for pancreatectomy) (Figure 2A), while insulin 
and C-peptide secretion were significantly reduced (P<0.01 and P<0.01 for pancreatectomy, 
respectively, Figure 2B-C).  
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Hemipancreatectomy induces a increase in proinsulin to insulin ratio, while its dynamic secretion is 
preserved. 
Proinsulin concentration changes over time tended to increase after surgery (P=0.08 for 
pancreatectomy), (Figure 2D). Insulin to proinsulin ratios showed increased time-dependent 
response both before and after surgery (P=0.01 for time), while no differences due to surgery were 
detectable. Fold change in proinsulin to insulin ratios increased considerably over time before and 
after surgery and the increase over time was significantly greater following surgery (P value for 
interaction=0.01) (Figure 2E). 
Insulin resistance induces amplified proinsulin to insulin ratio after hemipancreatectomy 
To further characterize changes in proinsulin to insulin ratio following removal of ~50% of 
pancreas, we investigated the correlations between insulin sensitivity (glucose infusion rate during 
the euglycemic hyperinsulinemic clamp) and  proinsulin to insulin ratio following pancreatectomy. 
The analysis of the entire cohort revealed strong inverse correlations, both in the fasting state (basal 
P/I ratio r= -0.78, P=0.01, Figure 3A) and as AUC after the meal test (AUC P/I ratio 0-240 min r=-
0.73, P=0.02, Figure 3B). 
In order to better characterize the relation between insulin sensitivity and changes in proinsulin to 
insulin ratio, we compared insulin resistant and insulin sensitive subjects.  
A trend to increase in basal ISR, total ISR, and also in beta cell glucose sensitivity  per  arginine-
stimulated insulin secretion was observed in both insulin sensitive and insulin resistant subjects 
following acute islet cell mass reduction (Supplementary Figure 2). 
Interestingly, basal proinsulin to insulin ratio (insulin sensitive 0.39±0.10 vs insulin resistant 
0.33±0.08, P=0.65; Supplementary Figure 3B) and total proinsulin to insulin ratio (AUC P/I ratio 0-
240 min insulin sensitive 68.2±20.3 vs insulin resistant 59.0±17.2, P=0.80, Supplementary Figure 
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1C) were comparable before surgery, while insulin secretion was significantly greater in insulin 
resistant subjects (P=0.03) (Supplementary Figure 4A). 
Although 50% pancreatectomy led to increased proinsulin to insulin ratio in the entire cohort, 
pancreatectomy had a significantly different and opposite effect on time-dependent change in 
proinsulin to insulin ratio in insulin sensitive compared to insulin resistant subjects. (P<0.001 for 
the interaction between pancreatectomy, time and insulin sensitivity. Supplementary Figure 3A) 
After partial pancreatectomy, all subjects experienced a significant reduction in insulin secretion 
and insulin levels were comparable in insulin sensitive compared to insulin resistant subjects 
(p=0.83) (Supplementary figure 4B), but only the insulin sensitive subjects showed a significant 
decrease in the basal proinsulin to insulin ratio (insulin sensitive before surgery 0.39±0.10 vs after 
surgery 0.20±0.07, P=0.02; Supplementary Figure 3A-B) and a numerical decrease in total 
proinsulin to insulin ratio (AUC P/I ratio 0-240 min insulin sensitive before surgery 68.2±20.3 vs 
after surgery 47.9±10.2, P=0.18; Supplementary Figure 3A-C). Conversely, in the insulin resistant 
subjects basal proinsulin to insulin ratio (insulin sensitive before surgery 0.33±0.08 vs after surgery 
0.46±0.08, P=0.04; Supplementary Figure 3A-B) and total proinsulin to insulin ratio increased after 
surgery (AUC P/I ratio 0-240 min insulin sensitive before surgery 59.0±16.2 vs after surgery 
78.1±21.4, P=0.04; Supplementary Figure 3A-C).  
DISCUSSION 
Our findings suggest that an acute per cell insulin secretion demand alters insulin secretion 
processes (proinsulin/insulin ratio) mainly in the presence of insulin resistance. The key result is 
that insulin sensitivity following partial pancreatectomy was strongly and inversely correlated with 
proinsulin to insulin ratio, measured either in the fasting state or after the mixed meal. 
To reproduce a condition of acute increased insulin secretory demand due to loss of islets of 
Langerhans, we used subjects undergoing a 50% pancreatectomy as a model. Following a ~50% 
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removal of islets of Langerhans, we observed a two-fold time-dependent increase in the proinsulin 
to insulin ratio (expressed as a fraction of the basal value) during a meal, suggesting that this 
increased beta cell workload affects proinsulin processing. 
In line with a previous study in which the surgical removal of two-thirds of the pancreas in dogs 
failed to reproduce a surgically induced change in the proinsulin to insulin ratio (22), no statistically 
significant changes in fasting P/I ratio were observed following acute beta cell mass reduction. This 
suggests that the imbalance in the insulin secretory machinery due to increasing beta cell demand 
occurs under stimulus. These data differ from those obtained in a study on pancreas donors 
following partial pancreatectomy (23), in which an increased fasting proinsulin to insulin ratio was 
observed after surgery and this was directly correlated with fasting glucose levels and measures of 
maximal beta cell reserve capacity. This controversial result could be explained by the different 
timing of the post-surgical evaluation. Indeed, while Seaquist et al. (23) evaluated donors no earlier 
than 12 months and up to 96 months after hemipancreatectomy, we performed a follow-up after a 
mean of 45 days. It seems that increased proinsulin to insulin ratio in the fasting state needs a 
chronic adaptation to increasing beta cell workload, which requires a long-term evaluation. 
Further, we also demonstrated that proinsulin/insulin ratio increases physiologically in a time-
dependent manner in the four hours after a meal and that this time-dependent secretion in response 
to meals is preserved following acute beta cell mass reduction. 
We must also account for the effect of hyperglycemia, as it is the major factor increasing insulin 
secretory demand, and the changes observed in our study are also mediated by worsening glucose 
control. 
We employed a mixed meal test which reproduces physiological stimulus to insulin secretion and 
represents an appropriate method to investigate the proinsulin response. This finding highlights the 
important role of appropriate stimuli in investigating insulin secretion dynamics. 
Despite preservation of the time-dependent proinsulin to insulin ratio following beta cell mass 
reduction, overall secretion increased after partial pancreatectomy, in the presence of a concomitant 
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worsening in beta cell secretion rate and glucose sensitivity, suggesting that the remaining beta cell 
mass is under stress due to the increased workload (likely due to a combination of insulin resistance 
and reduced beta cell mass). 
These data support our hypothesis that increased beta cell demand, rather than preexisting beta cell 
dysfunction per se, determines a rapid change in proinsulin to insulin secretion ratio, in line with 
earlier studies showing that increased proinsulin levels, which are the consequence of impaired 
proinsulin conversion to insulin, predict worsening glucose tolerance (24,25). 
Furthermore, both basal and stimulated levels of P/I ratio were comparable in insulin sensitive and 
insulin resistant subjects at baseline (before surgery), suggesting that underlying insulin resistance 
does not affect proinsulin secretion in normal physiological conditions. 
Earlier studies have been inconclusive regarding the relative fasting proinsulin levels in prediabetes, 
mainly because proinsulin and insulin were analyzed only at baseline, i.e. non stimulated samples. 
Several studies have shown an increase in the P/I ratio in IGT, obese and insulin resistant non-
diabetic individuals, suggesting that proinsulin conversion might be a useful biomarker for the 
prediction of diabetes risk and beta cell dysfunction (26-28), whereas others have found normal 
levels compared to controls (29-33). 
Despite the small population, it is worth noting that our data overcome the limits of previous studies 
on this relevant topic and we did our best to strengthen the study with a stronger statistical analysis. 
We therefore performed a mixed measures repeated statistical analysis, which includes every single 
time point in the outcome evaluation without violating the assumption of data independence while 
accounting for random effects. 
As there are differences in the half-lives of insulin and proinsulin (34), the circulating 
concentrations during the fasting state do not reflect what is actually released by the beta cell 
granules. Instead, measuring insulin secretion directly after acute stimulation provides a better 
estimate of the granule content of insulin and proinsulin. Larsson and Ahren (35) have shown an 
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increase in the P/I ratio after acute stimulation of insulin secretion with arginine in IGT women, but 
we were unable to demonstrate the same trend when comparing insulin sensitive to insulin resistant 
subjects before surgery, probably due to the use of a different stimulus. 
However, in response to increased beta cell workload following acute beta cell mass reduction, 
insulin resistant subjects showed an increase in both fasting and area under the curve proinsulin to 
insulin ratio, while the proinsulin to insulin ratio showed no increase in insulin sensitive subjects. 
Further, it seems less likely that intrinsic processing defects are involved, as otherwise one would 
expect the same response in the more and less insulin sensitive subgroups. 
Despite the acute onset of hyperglycemia (40 days), we cannot exclude that worsening insulin 
sensitivity, leading to glucose toxicity effects and structural modifications in the beta cells (as 
observed after many years of chronic hyperglycemia) may play a role in the proinsulin to insulin 
changes observed or that hyperglycemia and other metabolic parameters may also impair proinsulin 
processing. Further, we do not have functional follow-up reevaluation before 40 days and we cannot 
exclude that a different condition could be present a few hours/days after surgery. Nevertheless, we 
purposely chose to conduct follow-up reevaluation 40 days after surgery to ensure full recovery 
after this complex surgery and limit additional confounders due to the short period of recovery from 
the surgical procedure. 
Besides, in type 2 diabetes it has been demonstrated that P/I ratio is increased both in the fasting 
state (36-40) and after acute stimulation (41). It seems, therefore, that insulin resistance is a feature 
of prediabetes, in which there are compensatory attempts to cope with the various aspects of the 
beta cell dysfunction seen in diabetes, such as defective proinsulin processing in the granules. 
 
Furthermore, we here suggest that morphological and functional modifications induced by insulin 
resistance directly impact the beta cell secretory system, but that their negative effects become 
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evident only in response to supraphysiological beta cell demand, when probably no further 
compensation for increased beta cell workload is possible.  
 
In this context, the improvement of proinsulin to insulin conversion recently observed after lifestyle 
intervention and at long term follow-up is an important finding (42), as it suggests that in the early 
beta cell dysfunction phase, the defect in proinsulin processing could be partially reversed by 
improving insulin sensitivity. Investigating the mechanisms underlying defects in proinsulin 
secretion could reveal new potential therapeutic targets to slow or cure beta cell dysfunction, by 
applying personalized strategies for each single aspect of beta cell dysfunction. 
In summary, the proinsulin to insulin ratio increases after physiological stimulation of insulin 
secretion in non-diabetic humans, and this is further amplified following acute beta cell mass 
reduction. This indicates a physiological regulation in the proinsulin secretion process, which is 
significantly impaired after prolonged stimulation and when beta cell demand is increased following 
beta cell mass reduction. Thus, insulin resistance directly impacts proinsulin processing, leading to 
increased relative, both basal and stimulated, proinsulin release, detectable only in the presence of 
increased insulin secretion demand, due to acute beta cell mass reduction. 
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Table 1. 
Subject characteristics Before Surgery After Surgery P value 
Mean age (y) 55 ± 7.0 --- --- 
Gender (female/male) 7/2 --- --- 
BMI (kg/m
2
) 
27.8±1.63 25.2±1.32 0.17 
Fasting glucose (mg/dl) 88.0±6.00 117±12.0 0.01 
Fasting insulin (µIU/ml) 5.56±0.79 5.23±1.77 0.92 
Fasting C-peptide (ng/ml) 2.55±0.66 2.03±0.22 0.36 
Total Cholesterol (mg/dl)  203±23.4 144±19.9 0.03 
Triglycerides (mg/dl)  142±12.6 102±13.5 0.06 
HbA1c % (mmol/mol) 5.61±0.19 
(38.0±1.83) 
6.76±0.4 
(50.0±4.36) 
0.008 
Clinical and metabolic characteristics of patients before and after surgery. Data are means ± SE or 
n. (gender distribution), p- value <0.05 is considered statistically significant. 
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TABLE AND FIGURE LEGENDS 
Table 1. Clinical and metabolic characteristics of patients before and after surgery. Data are means 
± SE or n. (sex distribution and clinical diagnoses),* p- value significant <0.05. 
Figure 1. MMT-derived basal insulin secretion rate (A), total insulin secretion rate (B) and glucose 
sensitivity (C), Clamp-derived arginine-stimulated insulin secretion (D) before (white bars) and 
after (dark bars) partial pancreatectomy. 
Figure 2. Glucose (A), insulin (B) C-peptide (C), proinsulin (D) levels before (white circles) and 
after (dark squares) partial pancreatectomy. (E) Fold change in proinsulin to insulin ratio during 
MMT before (white circles) and after (dark squares) partial pancreatectomy. P<0.01 for 
pancreatectomy (A, B and C), P=0.08 for pancreatectomy (D), P value for interaction=0.01 (E). 
Figure 3. (A) Correlation between glucose uptake (insulin sensitivity index) and basal proinsulin to 
insulin ratio after partial pancreatectomy in all subjects. r= -0.78; P=0.01 (B) Correlation between 
glucose uptake (insulin sensitivity index) and total proinsulin to insulin ratio after partial 
pancreatectomy in all subjects r=-0.73; P=0.02. Insulin sensitive subjects  (black circles) and Insulin 
resistant subjects (white circles).  
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Figure 1. MMT-derived basal insulin secretion rate (A), total insulin secretion rate (B), glucose sensitivity (C) 
and clamp-derived arginine-stimulated insulin secretion (D) before (white bars) and after (dark bars) partial 
pancreatectomy.  
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Figure 2. Glucose (A), insulin (B) c-peptide (C), proinsulin (D) levels before (white circles) and after (dark 
squares) partial pancreatectomy. (E) Fold change in proinsulin to insulin ratio during MMT before (white 
circles) and after (dark squares) partial pancreatectomy . * P<0.01 for pancreatectomy (A,B and C), P=0.08 
for pancreatectomy (D), # P value for interaction=0.01 (E).  
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Figure 3. (A) Correlation between insulin sensitivity and basal proinsulin to insulin ratio after partial 
pancreatectomy in all subjects. r= -0.78; P=0.01  (B) Correlation between insulin sensitivity and total 
proinsulin to insulin ratio after partial pancreatectomy in all subjects r=-0.73; P=0.02. insulin sensitive 
subjects  (black circles) and Insulin resistant subjects (white circles).  
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Supplementary Table 1. 
 
 
Subject characteristics 
Insulin sensitive 
(n.5) 
Insulin resistant 
(n.4) 
 
Before 
Surgery 
After  
Surgery 
Before 
Surgery 
After  
Surgery 
Glucose Uptake (mg·Kg
-1
·min
-1
) 
6.29±0.44 5.97±0.31 3.56±0.46
*
 3.88±0.26 
BMI (kg/m
2
) 27.6±1.68 26.2±0.96 26.1±2.38 25.4±2.13 
Fasting glucose (mg/dl) 79.4±6.20 99.6±7.71
#
 95.7±3.49 139±18.0
§
 
Fasting Insulin (µUI/ml) 4.32±0.54 4.38±0.60 7.12±1.18
*
 6.30±3.41 
Fasting C-peptide (ng/ml) 1.50±0.18 1.78±0.14 3.77±1.18 2.35±0.95 
Total Cholesterol (mg/dl) 182±26.1 144±25.7 229±41.9 132±16.6 
Triglycerides (mg/dl) 135±28.6 102±15.8 150±21.4 102±13.2 
HbA1c (%) 5.58±0.22  5.94±0.24 5.65±0.23 7.60±0.34
§
 
HbA1c (mmol/mol) 37.4±2.50 38.2±2.54 41.4±2.64 59.5±3.81
§
 
Clinical and metabolic characteristics of insulin sensitive and insulin resistant patients before and 
after surgery. Data are means ± SE, * P- value <0.05 is considered statistically significant insulin 
sesnsitive vs insulin resistant before surgery. 
#
 P- value <0.05 is considered statistically significant 
before vs after surgery in insulin sensitive. § P- value <0.05 is considered statistically significant 
before vs after surgery in insulin resistant. 
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